EMBRACA试验最终总生存结果:他拉唑帕利对比化疗治疗gBRCA1/2突变HER2阴性晚期乳腺癌
EMBRACA是一项随机III期试验,纳入gBRCA1/2突变HER2阴性晚期乳腺癌患者,比较他拉唑帕利与医生选择的化疗。最终分析显示,他拉唑帕利对比化疗的总生存HR为0.848(95%CI 0.670-1.073;P=0.17),中位OS分别为19.3个月和19.5个月,差异无统计学意义;校正后续治疗影响后HR为0.756(95% bootstrap CI 0.503-1.029)。患者报告结局持续支持他拉唑帕利。
要点
- 他拉唑帕利对比化疗未显著改善gBRCA1/2突变HER2阴性ABC的总生存。
- 中位OS分别为19.3个月和19.5个月,HR 0.848(95%CI 0.670-1.073;P=0.17)。
- 患者报告结局持续支持他拉唑帕利优于化疗。
核心结论
- 在gBRCA1/2突变HER2阴性晚期乳腺癌中,他拉唑帕利对比化疗未显著改善总生存,后续治疗可能影响分析。
- 安全性与此前报告一致,患者报告结局持续支持他拉唑帕利。
研究设计与样本
- 随机III期EMBRACA试验纳入gBRCA1/2突变HER2阴性晚期乳腺癌患者。
- 患者随机接受他拉唑帕利或医生选择的化疗,共431例入组随机(他拉唑帕利287例/化疗144例),412例接受治疗(他拉唑帕利286例/化疗126例)。
- 总生存采用分层HR和对数秩检验分析,并预设采用秩保持结构失效时间模型校正后续治疗影响。
主要发现
- 截至2019年9月30日,他拉唑帕利组死亡216例(75.3%),化疗组死亡108例(75.0%);中位随访分别为44.9个月和36.8个月。
- 他拉唑帕利对比化疗的总生存HR为0.848(95%CI 0.670-1.073;P=0.17),中位OS分别为19.3个月(95%CI 16.6-22.5)和19.5个月(95%CI 17.4-22.4)。
- Kaplan-Meier生存率(他拉唑帕利/化疗):12个月71%(66%-76%)/74%(66%-81%);24个月42%(36%-47%)/38%(30%-47%);36个月27%(22%-33%)/21%(14%-29%)。
- 校正后续PARP抑制剂和/或铂类使用后,总生存HR为0.756(95% bootstrap CI 0.503-1.029)。
- 3-4级不良事件发生率为他拉唑帕利69.6%、化疗64.3%,与此前报告一致;延长随访显示全球健康状况/生活质量和乳腺症状的确定性临床意义恶化时间显著延迟,支持他拉唑帕利(所有P<0.01)。
关键数值与推荐
- 总生存HR 0.848(95%CI 0.670-1.073;P=0.17),中位OS 19.3个月对比19.5个月。
- 校正后续治疗后总生存HR 0.756(95% bootstrap CI 0.503-1.029)。
- 他拉唑帕利组46.3%接受后续铂类、4.5%接受后续PARP抑制剂;化疗组41.7%接受后续铂类、32.6%接受后续PARP抑制剂。
临床怎么用
- 对于gBRCA1/2突变HER2阴性晚期乳腺癌,他拉唑帕利虽未显著改善总生存,但患者报告结局持续支持其使用。
- 后续PARP抑制剂和铂类治疗可能影响总生存分析,临床解读需考虑治疗序列。
局限性
- 后续治疗(尤其是PARP抑制剂和铂类)的不平衡可能混淆总生存分析。
- 预设的秩保持结构失效时间模型校正后HR的95%bootstrap CI上限超过1,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In EMBRACA, talazoparib prolonged progression-free survival versus chemotherapy (hazard ratio [HR] 0.542 [95% confidence interval (CI) 0.413-0.711]; P < 0.0001) and improved patient-reported outcomes (PRO) in germline BRCA1/2 (gBRCA1/2)-mutated advanced breast cancer (ABC). We report final overall survival (OS). PATIENTS AND METHODS: This randomized phase III trial enrolled patients with gBRCA1/2-mutated HER2-negative ABC. Patients received talazoparib or physician's choice of chemotherapy. OS was analyzed using stratified HR and log-rank test and prespecified rank-preserving structural failure time model to account for subsequent treatments. RESULTS: A total of 431 patients were entered in a randomized study (287 talazoparib/144 chemotherapy) with 412 patients treated (286 talazoparib/126 chemotherapy). By 30 September 2019, 216 deaths (75.3%) occurred for talazoparib and 108 (75.0%) chemotherapy; median follow-up was 44.9 and 36.8 months, respectively. HR for OS with talazoparib versus chemotherapy was 0.848 (95% CI 0.670-1.073; P = 0.17); median (95% CI) 19.3 months (16.6-22.5 months) versus 19.5 months (17.4-22.4 months). Kaplan-Meier survival percentages (95% CI) for talazoparib versus chemotherapy: month 12, 71% (66% to 76%)/74% (66% to 81%); month 24, 42% (36% to 47%)/38% (30% to 47%); month 36, 27% (22% to 33%)/21% (14% to 29%). Most patients received subsequent treatments: for talazoparib and chemotherapy, 46.3%/41.7% received platinum and 4.5%/32.6% received a poly(ADP-ribose) polymerase (PARP) inhibitor, respectively. Adjusting for subsequent PARP and/or platinum use, HR for OS was 0.756 (95% bootstrap CI 0.503-1.029). Grade 3-4 adverse events occurred in 69.6% (talazoparib) and 64.3% (chemotherapy) patients, consistent with previous reports. Extended follow-up showed significant overall improvement and delay in time to definitive clinically meaningful deterioration in global health status/quality of life and breast symptoms favoring talazoparib versus chemotherapy (P < 0.01 for all), consistent with initial analyses. CONCLUSIONS: In gBRCA1/2-mutated HER2-negative ABC, talazoparib did not significantly improve OS over chemotherapy; subsequent treatments may have impacted analysis. Safety was consistent with previous observations. PRO continued to favor talazoparib.
引用
- Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020. PMID: 32828825. doi:10.1016/j.annonc.2020.08.2098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。